tirzepatide surpass 4 versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial The Association Between Tirzepatide Versus

8.1% WL vs

The trial involved 1879 patients with inadequate glycemic control on metformin monotherapy, who were randomly assigned to receive tirzepatide at doses of 5 mg, 10 mg, or 15 mg, or semaglutide at a dose of 1 mg.After 40 weeks of treatment, all doses of tirzepatide were found to be noninferior and superior to semaglutide in terms of reducing glycated hemoglobin (HbA1c) levels

Within the Peptides and neurological research sectors, it is highly valued for its technical role in promoting synaptogenesis and enhancing cognitive functions in laboratory models

In another study, Wang et al

Neural insensitivity to the effects of hunger in women remitted from anorexia nervosa